pimozide

Pimozide is a first-generation (typical) antipsychotic of the diphenylbutylpiperidine class, primarily indicated for the suppression of motor and phonic tics in patients with Tourette's disorder who have not responded to other treatments. It acts mainly by antagonizing dopamine receptors in the central nervous system, particularly D2, D3, and D4 receptors, as well as the serotonin 5‑HT7 receptor. This dopaminergic blockade reduces tic severity but can also lead to extrapyramidal side effects and hyperprolactinemia. Pimozide is also used off-label for schizophrenia and certain psychiatric or movement disorders when other therapies are ineffective or contraindicated[1][3][4][6]. The drug was originally developed by Janssen Pharmaceutica.

Brand names

OrapMozepLarapPimodac

Other names

PimozidaPimozidum